Byondis
Byondis is a Dutch biopharmaceutical company developing proprietary antibody-drug conjugate (ADC) technology platforms for cancer treatment; following its December 2025 strategic transformation, it focuses on licensing these platforms and partnered programs rather than independent clinical development.
- Company typePrivate
- Founded2007
- HeadquartersNijmegen, Netherlands
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
Byondis firmographics
Firmographics- Name
- Byondis
- Legal name
- Byondis B.V.
- Website
- https://byondis.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Byondis is a Dutch biopharmaceutical company developing proprietary antibody-drug conjugate (ADC) technology platforms for cancer treatment; following its December 2025 strategic transformation, it focuses on licensing these platforms and partnered programs rather than independent clinical development.
- Ownership category
- akta.pro rank
Byondis industry classification
Industry- Product category
- Oncology Biopharmaceuticals / Antibody-Drug Conjugates
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)
- akta.pro secondary industries
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)
Keywords
Where Byondis is headquartered
LocationHeadquarters
- HQ city
- Nijmegen
- HQ country
- Netherlands
- HQ region
- Europe
Offices3 records
Markets served
Byondis business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Licensing and Royalties: Byondis generates revenue through licensing agreements for its ADC technologies and pipeline assets. The company receives upfront payments, sales royalties, and milestone payments upon achievement of development and sales targets. Partner medac has exclusive license to commercialize SYD985 in EU, UK and other European countries.
- Drug Development and Commercialization: As a clinical-stage biopharmaceutical company, Byondis develops proprietary ADC therapies through clinical stages with the intention of partnering or commercializing directly upon regulatory approval.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
Byondis product offering
Product offeringCore offering
Byondis is a biopharmaceutical company developing proprietary antibody-drug conjugate (ADC) technology platforms and targeted precision medicines for intractable cancers and autoimmune diseases. The company operates fully integrated in-house R&D and GMP manufacturing facilities in Nijmegen, Netherlands, and after a December 2025 strategic transformation is focused on licensing and partnering its ADC platforms (ByonZine®, ByonNative®, ByonShieLD®, ByonFoLD®, ByonBranch®, ByonGuard™, ByonBoost™, and the Antifolate Linker-Drug Platform) to pharmaceutical and biotech partners.
Product overview
Byondis is a fully integrated Dutch biopharmaceutical company developing targeted cancer medicines, primarily antibody-drug conjugates (ADCs) and monoclonal antibodies. The company's portfolio is organized around proprietary technology platforms — including ByonZine® (duocarmazine linker-drug), ByonShieLD® (site-specific conjugation), ByonNative®, ByonFoLD® (dual-payload), ByonBranch® (branched linker), ByonGuard™ (universal masking), ByonBoost™ (phosphonate immunostimulatory), and an Antifolate linker-drug platform — which collectively generate pipeline candidates. Clinical-stage programs include SYD985 ([vic-]trastuzumab duocarmazine) targeting HER2-positive cancers, BYON3521 (c-MET-targeting ADC), and previously BYON4228 and BYON4413 prior to discontinuation in the December 2025 strategic transformation. The company operates fully integrated in-house R&D and GMP manufacturing facilities in Nijmegen, the Netherlands.
Differentiator
Problem solved
Functional benefit
Products and services
- SYD985 ([vic-]Trastuzumab Duocarmazine) Next-generation anti-HER2 antibody-drug conjugate (ADC) using Byondis' proprietary ByonZine® duocarmazine linker-drug technology for HER2-positive metastatic breast cancer and other HER2-expressing cancers. Licensed to medac GmbH for European commercialization.
- BYON3521 c-MET-targeting antibody-drug conjugate using site-specific ByonShieLD® conjugation and ByonZine® linker-drug technology, in Phase I clinical study for c-MET-expressing solid tumors.
- SYD1875 Next-generation antibody-drug conjugate targeting the 5T4 oncofetal antigen using Byondis' proprietary vc-seco-DUBA linker-drug and site-specific HC-41C conjugation technology, in Phase I study for 5T4-expressing solid tumors.
- ByonZine® Linker-Drug Technology Platform Proprietary cleavable DNA-damaging duocarmazine linker-drug platform enabling ADCs to eliminate heterogeneous tumors via target-mediated and bystander mechanisms, killing both dividing and non-dividing cancer cells with extremely low free-drug levels in circulation. Available for licensing to ADC developers.
- ByonNative® Antibody Conjugation Platform Differentiated antibody conjugation platform enabling ADC generation via partially reduced native disulfide bonds with proprietary process to remove unwanted non-conjugated and over-conjugated species, enabling rapid generation of ByonZine® ADCs.
- ByonShieLD® Site-Specific Conjugation Platform Site-specific antibody conjugation platform creating uniform ByonZine® ADCs via orthogonal cysteine activation and conjugation; shielding of hydrophobic payload yields ADCs with superior therapeutic index and manufacturability.
- ByonFoLD® Dual Linker-Drug Platform Dual linker-drug antibody conjugation platform producing well-defined two-in-one ADCs in which two different payloads are conjugated compatibly to a single antibody, enabling next-generation ADCs with synergistically operating dual payloads.
- ByonBranch® Branched Linker Technology Branched linker technology allowing coupling of payloads to an antibody resulting in ADCs with reduced hydrophobicity.
- ByonGuard™ Universal Masking Platform Universal masking platform designed to improve therapeutic index of antibody-based therapies by limiting binding in healthy tissues and restoring full target engagement in tumors, with no bespoke peptides required.
- ByonBoost™ Phosphonate Linker-Drug Platform Phosphonate linker-drug platform engineered to activate Vγ9Vδ2 (γδ) T cells in the tumor microenvironment, enabling targeted delivery with immunologic anti-tumor effect; compatible with single- and dual-payload concepts for solid oncology and hematological malignancies.
- Antifolate Linker-Drug Platform ADC linker-drug platform providing a differentiated mechanism targeting dihydrofolate reductase (DHFR), designed to overcome resistance and systemic side effects of current ADC treatments, with broad applicability across treatment lines and tumor types. Available for licensing.
Quantifiable outcome
- Phase III TULIP study demonstrated 7.0 months median PFS for SYD985 vs 4.9 months for physician's choice (HR 0.64, p=0.002)
- +2 more outcomes
Companies that use Byondis
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
Byondis technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature8 records
Byondis partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core, minor and major.
- medac GmbHcoreLicense and Collaboration Agreement with Supply Agreement. medac receives exclusive license to commercialize SYD985 in EU, UK, and further European countries (Iceland, Liechtenstein, Norway, Switzerland) in all approved indications. Byondis receives undisclosed upfront payment, sales royalties, and milestone payments upon achievement of development and sales targets. medac will be the marketing authorization applicant for European markets.
- GlycotopecorePlatform access agreement for discovery and development of antibodies against novel GlycoTargets. Byondis gains exclusive rights to evaluate and develop antibodies against selected novel GlycoTargets with option to in-license for ADC development. Glycotope's tumor-specific carbohydrate antibodies combined with Byondis' linker-drug platforms aim to produce novel ADC treatments.
- GlaxoSmithKline (Niraparib supply)minorPhase I study (SYD985.004) exploring synergistic effects of SYD985 in combination with PARP inhibitor niraparib. Niraparib supplied for clinical trial evaluation in HER2-expressing solid tumors.
- Quantum Leap Healthcare CollaborativemajorCollaboration for I-SPY 2 TRIAL investigating neoadjuvant use of SYD985 in HER2-low early-stage breast cancer. Quantum Leap provides clinical sites and expertise while Byondis supplies investigational drug and financial/regulatory support. Quantum Leap leads pre-competitive consortium including FDA, industry, patient advocates, and clinicians from 16 major US cancer research centers.
Scale indicators6 records
Recent moves8 records
Expansion highlights5 records
Byondis competitors and assessment
Company assessmentDirect peers
- ADC Therapeutics: Commercial-stage ADC company with approved Zynlonta and a pipeline built around proprietary pyrrolobenzodiazepine (PBD) payloads. Comparable as a focused ADC platform company developing multiple candidates with differentiated linker-drug technology.
- Mersana Therapeutics: Clinical-stage ADC developer with proprietary payload and conjugation platforms (Dolasynthen, Immunosynthen). Directly comparable as a similarly-sized private/public ADC platform company pursuing differentiated linker-payload chemistries.
- Heidelberg Pharma: German ADC developer commercializing the proprietary amanitin payload platform (ATAC technology). Directly comparable as a European ADC platform player with proprietary payloads targeting novel mechanisms of action.
Broad incumbents
- Daiichi Sankyo: Global leader in ADC technology (DXd platform underlying Enhertu and Datroway). Comparable as the dominant ADC platform incumbent whose linker-payload IP sets the benchmark Byondis' platforms must differentiate against.
- ImmunoGen (AbbVie): Pioneer of ADC technology and originator of the DM4/DM1 maytansinoid platforms; now part of AbbVie. Comparable as an established ADC platform player with multiple approved ADCs and a deep pipeline of linker-payload programs.
Emerging players
- Tubulis: European ADC biotech developing proprietary conjugation platforms (P5 and TAAP) for tunable ADCs with improved stability and therapeutic index. Comparable as a smaller ADC platform company with proprietary linker and conjugation IP targeting differentiated ADC design.
- Pyxis Oncology: Early-to-mid-stage ADC developer with multiple programs and proprietary conjugation approaches. Comparable as a smaller ADC platform company pursuing novel payloads and tumor-targeting strategies.
- ProfoundBio: Clinical-stage ADC company with proprietary hydrophilic linker technology (ProLinker) and topoisomerase-based payloads. Comparable as an emerging ADC platform developer focused on improving therapeutic index through differentiated linker chemistry.
Regional players
- WuXi XDC: China-based ADC-focused CDMO offering end-to-end discovery, development, and manufacturing services for ADCs. Comparable as a regional player offering integrated ADC capabilities, although positioned as a contract manufacturer rather than product developer.
- Innovent Biologics: Chinese biopharmaceutical company with multiple ADC candidates in clinical development, including collaborations leveraging proprietary payloads. Comparable as a regional player building an oncology franchise with ADC pipeline depth.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Byondis social profiles
Digital presenceByondis financial estimates
Financial estimateRevenue estimate
Valuation estimate
Byondis leadership team
Management profileNumber of profiles
Profiles11 records
Byondis funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Byondis M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Byondis
What does Byondis do?
Byondis is a biopharmaceutical company developing proprietary antibody-drug conjugate (ADC) technology platforms and targeted precision medicines for intractable cancers and autoimmune diseases. The company operates fully integrated in-house R&D and GMP manufacturing facilities in Nijmegen, Netherlands, and after a December 2025 strategic transformation is focused on licensing and partnering its ADC platforms (ByonZine®, ByonNative®, ByonShieLD®, ByonFoLD®, ByonBranch®, ByonGuard™, ByonBoost™, and the Antifolate Linker-Drug Platform) to pharmaceutical and biotech partners.
Is Byondis a public or private company?
Byondis is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Byondis founded?
Byondis was founded in 2007. It employs 251 to 500 people.
Where is Byondis based?
Byondis is headquartered in Nijmegen, Netherlands, in the Europe region.
How does Byondis make money?
Two revenue lines are on record. Licensing and Royalties are the primary driver. The others are drug Development and Commercialization.
Who are Byondis's main competitors?
Direct peers on record are ADC Therapeutics, Mersana Therapeutics and Heidelberg Pharma. Broad incumbents are Daiichi Sankyo and ImmunoGen (AbbVie). Emerging players are Tubulis, Pyxis Oncology and ProfoundBio. Regional players are WuXi XDC and Innovent Biologics.
Does Byondis have an API?
No public API is recorded for Byondis.
What industry is Byondis in?
Byondis's product category is Oncology Biopharmaceuticals / Antibody-Drug Conjugates. Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 325414 and its SIC code is 2836.